Physicians Financial Services Inc. Sells 5,293 Shares of Pfizer Inc. (NYSE:PFE)

Physicians Financial Services Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 13.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 33,696 shares of the biopharmaceutical company’s stock after selling 5,293 shares during the quarter. Physicians Financial Services Inc.’s holdings in Pfizer were worth $975,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Philip James Wealth Mangement LLC bought a new stake in shares of Pfizer during the 3rd quarter valued at $10,109,000. Winthrop Advisory Group LLC grew its stake in shares of Pfizer by 2.6% during the third quarter. Winthrop Advisory Group LLC now owns 15,834 shares of the biopharmaceutical company’s stock worth $458,000 after purchasing an additional 397 shares during the period. Verity Asset Management Inc. lifted its stake in Pfizer by 31.5% in the third quarter. Verity Asset Management Inc. now owns 64,136 shares of the biopharmaceutical company’s stock valued at $1,851,000 after buying an additional 15,364 shares during the period. Lewis Asset Management LLC boosted its holdings in Pfizer by 16.7% during the third quarter. Lewis Asset Management LLC now owns 32,839 shares of the biopharmaceutical company’s stock worth $950,000 after buying an additional 4,695 shares during the last quarter. Finally, Mine & Arao Wealth Creation & Management LLC. bought a new stake in shares of Pfizer in the 3rd quarter valued at about $203,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Activity

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PFE. Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Stock Down 1.7 %

Shares of NYSE PFE traded down $0.46 during trading hours on Friday, hitting $27.00. The company had a trading volume of 8,356,099 shares, compared to its average volume of 37,364,316. The stock has a market capitalization of $153.01 billion, a P/E ratio of 37.11, a price-to-earnings-growth ratio of 0.88 and a beta of 0.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The firm’s 50 day moving average is $28.96 and its 200-day moving average is $28.64. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The company’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) EPS. On average, analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.22%. Pfizer’s dividend payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.